Newsmeme!
Discover News you didn't know existed
Metabolite
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Popular Antidepressant Blocks Beneficial Effects Of Tamoxifen In Breast Cancer
Published February 10, 2010, 6:08 am, redOrbit
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort studyWomen with breast cancer who take the antidepressant paroxetine at the same time as tamoxifen are at an increased risk of death, concludes a study published on bmj.com Feb.
Takeda Announces Initiation Of Trial To Study The Concomitant Use Of Dexlansoprazole And Other Proton Pump Inhibitors ...
Published February 10, 2010, 3:43 am, Medical News Today
Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration ...
Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial
Published February 10, 2010, 3:26 am, News-Medical-Net
Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug ...
Breast cancer patients taking antidepressant paroxetine at the same time as tamoxifen are at increased risk of death
Published February 10, 2010, 2:25 am, News-Medical-Net
Women with breast cancer who take the antidepressant paroxetine at the same time as tamoxifen are at an increased risk of death, concludes a study published on bmj.com today.
Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors ...
Published February 9, 2010, 9:09 am, redOrbit
DEERFIELD, Ill., Feb.
Antidepressant reduces effectiveness of cancer drug
Published February 9, 2010, 7:11 am, Canada.com
Paxil, an antidepressant commonly prescribed to women with breast cancer, can reduce or even abolish the effects of the breast-cancer drug tamoxifen, increasing a woman's risk of death.
Antidepressant blocks tamoxifen benefit: study
Published February 9, 2010, 6:46 am, CTV.ca
Paxil, a commonly-prescribed antidepressant, may interfere with the breast cancer drug tamoxifen, Canadian researchers have found. The interaction appears to increase the risk the cancer could return, the study found.
Metabolite Common Among Cancers
Published February 9, 2010, 6:34 am, Medical News Today
A study published online on February 8 in the Journal of Experimental Medicine reports that several distinct mutations found in a subset of patients with acute myelogenous leukemia (AML) result in excess production of the same metabolite. The enzyme isocitrate dehydrogenase 1 (IDH1), which normally facilitates production of the metabolite {alpha}-ketoglutarate, is mutated in approximately 80% of ...
Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors ...
Published February 9, 2010, 6:17 am, Marketwire
DEERFIELD, IL--(Marketwire - February 9, 2010) - Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and ...
Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors ...
Published February 9, 2010, 6:00 am, PR Newswire via Yahoo! Finance
Takeda Global Research & Development Center, Inc., U.S., announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors affect the pharmacokinetics and pharmacodynamics of Plavix in healthy subjects.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |